1. Evaluation of the efficacy and tolerability of UCB L059 (500 and 1000 mg b.i.d.,tablets) add-on treatment in refractory epileptic patients with partial onset seizures: a 32-week double-blind placebo-controlled crossover multicenter trial UCB S.A.Pharma Sector
2. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures;Shorvon;Epilepsia,2000
3. A 24-week multicentered, double-blind, parallel group, add-on study to compare the efficacy and the tolerability of 2 oral daily doses of UCB L059 (2000 mg and 4000 mg tablets) with placebo in patients with refractory epilepsy, followed by a 24-week open-label active treatment UCB S.A. Pharma Sector
4. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy;Betts;Seizure,2000
5. Evaluation of the efficacy and tolerability of UCB L059 (500 and 1500 mg bid, tablets) add-on treatment in epileptic patients with partial onset seizures: a 38-week, double-blind, placebo-controlled, parallel-group multicenter trial UCB S.A. Pharma Sector